98%
921
2 minutes
20
Background: Hepatitis delta virus (HDV) is a defective agent that only replicates in the presence of the hepatitis B virus. Accordingly, HDV acquisition may occur as superinfection of HBsAg+ carriers or following acute dual HDV and hepatitis B virus exposure. Herein, we examined the global and incident rates of HDV infections in Spain.
Patients And Methods: The presence of anti-HDV antibody and new HDV superinfections was examined in all HBsAg+ patients who attended one large tertiary outclinic in Spain since year 2000. Anti-HDV antibodies were tested repeatedly every 5 years in those previously negative.
Results: During a median follow-up of 12 years, 478 individuals were diagnosed as HBsAg+. Overall, 64.4% were male, median age was 55 years, 88.1% were native Spaniards, 6.5% were coinfected with HIV, and 7.3% were reactive for hepatitis C virus (HCV) antibodies.A total of 19 (4%) patients had anti-HDV antibody at first diagnosis. There were no further HDV seroconversions. Most anti-HDV+ patients were male (n=12), former injection drug users (n=13), and native Spaniards (n=16). Coinfection with HIV was found in six, and 12 had HCV antibodies. Interestingly, three of seven women with delta hepatitis were foreigners (Asian or African), denied injection drug use, were younger than 40 years old, and negative for both HCV and HIV.
Conclusion: The prevalence of chronic hepatitis delta is currently very low (<5%) among chronic HBsAg+ carriers in Spain, with lower rates in recent years. Moreover, new incident HDV infections were not seen in 478 chronic hepatitis B carriers since year 2000, following drastic declines in injection drug use.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MEG.0000000000001163 | DOI Listing |
Medicine (Baltimore)
September 2025
College of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Observational studies suggest associations between elevated body mass index (BMI) and autoimmune liver diseases (AILDs), yet causal evidence remains limited. This Mendelian randomization (MR) study aimed to elucidate the causal role of BMI in AILDs and identify mediating pathways involving 91 circulating cytokines. Utilizing public genome-wide association study data, univariate and multivariate MR analyses were conducted to assess causal relationships between BMI and 3 AILDs.
View Article and Find Full Text PDFDiagn Microbiol Infect Dis
September 2025
French National Reference Center for Hepatitis B, C and delta Viruses, Department of Virology, Hôpital Henri Mondor, Créteil, France; INSERM U955, Créteil, France. Electronic address:
Measurement of hepatitis B virus (HBV) DNA levels is the standard of care for diagnosis active HBV infection, assessing disease severity and prognosis, and guiding treatment decisions and monitoring response to therapy. In the study, the analytical and clinical performance of the ELITe InGenius System for quantifying HBV DNA was evaluated. A total of 377 of archived EDTA plasma or serum specimens were tested.
View Article and Find Full Text PDFClin Res Hepatol Gastroenterol
September 2025
Faculty of Medicine, Free University of the Great Lakes Countries, Goma, DR Congo; Department of research, Medical Research Circle (MedReC), Goma, DR Congo. Electronic address:
Antiviral Res
September 2025
Department of Infection, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address:
Background: Hepatitis D virus (HDV) infection is the most severe form of human viral hepatitis. A poor virus-specific CD8T cell response may result in persistent HDV infection. We investigated anti-viral effect and mechanisms of ubiquitinated small hepatitis D antigen (Ub-S-HDAg) in HBV/HDV superinfected liver organoids.
View Article and Find Full Text PDFLiver Int
October 2025
Gastroenterology, Hepatology and Transplantation Division, ASST Papa Giovanni XXIII, Bergamo, Italy.
Background And Aims: Hepatitis B (HBV) and Hepatitis Delta virus (HDV) infection have undergone significant changes in Italy over the past few decades, but reliable and updated prevalence of chronic hepatitis B (CHB) and Delta (CHD) data are lacking. The aim of the study was to describe the epidemiology of CHB and CHD in Italy in 2024, based on real-world data.
Methods: The number of patients with a healthcare expenditure exemption for CHB (016.